Celsion Corporation  

(Public, NASDAQ:CLSN)   Watch this stock  
Find more results for CLSN
2.52
+0.02 (0.95%)
Real-time:   11:45AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.51 - 2.58
52 week 2.15 - 3.73
Open 2.54
Vol / Avg. 30,333.00/414,859.00
Mkt cap 50.49M
P/E     -
Div/yield     -
EPS -1.38
Shares 19.98M
Beta 1.69
Inst. own 17%
May 12, 2015
Q1 2015 Celsion Corp Earnings Call - 11:00AM EDT - Add to calendar
Mar 12, 2015
Full Year 2014 Celsion Corp Earnings Call
Mar 12, 2015
Full Year 2014 Celsion Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -5164.64% -5098.85%
Operating margin -4973.99% -4900.25%
EBITD margin - -4592.12%
Return on average assets -36.92% -45.38%
Return on average equity -72.19% -79.24%
Employees 28 -
CDP Score - -

Address

997 Lenox Dr Ste 100
LAWRENCE TOWNSHIP, NJ 08648-2317
United States - Map
+1-609-8969100 (Phone)
+1-609-8962200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Celsion Corporation is an oncology drug development company. The company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. Its lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. Its pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence.

Officers and directors

Jeffrey W. Church CPA Chief Financial Officer, Senior Vice President - Corporate Strategy and Investor Relations
Age: 57
Bio & Compensation  - Reuters
Khursheed Anwer Ph.D. Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
Age: 55
Bio & Compensation  - Reuters
Nicholas Borys M.D. Vice President, Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Michael H. Tardugno Executive Chairman of the Board, President, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Pok Yu Chow Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Frederick J. Fritz Independent Director
Age: 63
Bio & Compensation  - Reuters
Robert W. Hooper Independent Director
Age: 67
Bio & Compensation  - Reuters
Alberto R. Martinez M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters